European Medicines Agency recommends licence for cladribine (Mavenclad)

The European Medicines Agency has approved cladribine (brand name Mavenclad) for use with multiple sclerosis. The agency has recommended that a licence should be granted, by the European Commission, for the treatment of highly-active relapsing MS. Cladribine is currently an anti-cancer drug under the brand names Leustat and Litak. The next step in the process … Continue reading European Medicines Agency recommends licence for cladribine (Mavenclad)